Your browser doesn't support javascript.
loading
A new phototherapy regimen during winter as an add-on therapy, coupled with oral vitamin D supplementation, for the long-term control of atopic dermatitis: study protocol for a multicentre, randomized, crossover, pragmatic trial - the PRADA trial.
Droitcourt, Catherine; Barbarot, Sébastien; Maruani, Annabel; Darrieux, Laure; Misery, Laurent; Brenaut, Emilie; Adamski, Henri; Chabbert, Cécile; Vermersch, Annie; Weiborn, Marie; Seneschal, Julien; Taïeb, Alain; Plantin, Patrice; Maillard, Hervé; Phan, Alice; Skowron, François; Viguier, Manuelle; Staumont-Salle, Delphine; Nosbaum, Audrey; Soria, Angèle; Barbaud, Annick; Oger, Emmanuel; Dupuy, Alain.
Afiliación
  • Droitcourt C; Univ Rennes, Rennes, France. catherine.droitcourt@chu-rennes.fr.
  • Barbarot S; Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.
  • Maruani A; INSERM, CIC 1414, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.
  • Darrieux L; EA 7449 REPERES "Pharmaco-epidemiology and Health Services Research", Univ Rennes, 35000, Rennes, France. catherine.droitcourt@chu-rennes.fr.
  • Misery L; Department of Dermatology, University Hospital Center of Nantes, 44000, Nantes, France.
  • Brenaut E; Department of Dermatology, University Hospital Center of Tours, 37000, Tours, France.
  • Adamski H; Department of Dermatology, Hospital Center of Saint-Brieuc, 22000, Saint-Brieuc, France.
  • Chabbert C; Department of Dermatology, University Hospital Center of Brest, 29000, Brest, France.
  • Vermersch A; Department of Dermatology, University Hospital Center of Brest, 29000, Brest, France.
  • Weiborn M; Department of Dermatology, University Hospital Center of Rennes, Pontchaillou Hospital, 2 rue Henri le Guilloux, 35000, Rennes, France.
  • Seneschal J; Department of Dermatology, Hospital Center of Perigueux, 24000, Perigueux, France.
  • Taïeb A; Department of Dermatology, Hospital Center of Valenciennes, 62000, Valenciennes, France.
  • Plantin P; Department of Dermatology, Hospital Center of Valenciennes, 62000, Valenciennes, France.
  • Maillard H; Department of Dermatology, University Hospital Center of Bordeaux, 33000, Bordeaux, France.
  • Phan A; Department of Dermatology, University Hospital Center of Bordeaux, 33000, Bordeaux, France.
  • Skowron F; Department of Dermatology, Hospital Center of Quimper, 29000, Quimper, France.
  • Viguier M; Department of Dermatology, Hospital Center of Le Mans, 72000, Angers, France.
  • Staumont-Salle D; Department of Dermatology, University Hospital Center of Lyon, 69000, Lyon-Bron, France.
  • Nosbaum A; Department of Dermatology, Hospital Center of Valence, 26000, Valence, France.
  • Soria A; Department of Dermatology, University Hospital Center of Reims, 51000, Reims, France.
  • Barbaud A; Department of Dermatology, University Hospital Center of Lille, 59000, Lille, France.
  • Oger E; Department of Dermatology, University Hospital Center of Lyon, 69000, Lyon Sud, France.
  • Dupuy A; Department of Dermatology and Allergology, University Hospital Center of Paris-Tenon, 75020, Paris, France.
Trials ; 20(1): 184, 2019 Mar 25.
Article en En | MEDLINE | ID: mdl-30909923
ABSTRACT

BACKGROUND:

Atopic dermatitis is a highly prevalent, chronic, relapsing disease in both adults and children. On the severity spectrum, lower-end patients benefit from small amounts of topical anti-inflammatory treatments (TAT), whereas higher-end patients need systemic immunosuppressants; in-between patients are treated with TAT and phototherapy. The major therapeutic challenge in this population is the long-term control of disease activity, and the current TAT-based pro-active strategy does not meet all their needs. Immunosuppressants are used as long-term control add-on treatments, but they are restricted to the most severely affected patients because of safety concerns. In addition, neither immunosuppressants nor other strategies have been properly evaluated in the long term despite long-term control having been acknowledged as one of the most important core outcome domains to be targeted in atopic dermatitis trials. Safe add-on therapies, rigorously evaluated for long-term control of the disease, are therefore needed. Phototherapy and vitamin D supplementation are both good candidates.

METHODS:

This is a multicenter, national, randomized, superiority, crossover trial testing add-on phototherapy (one winter under spaced sessions of phototherapy and one winter under observation) among subjects receiving standard care (i.e., TAT). On the same population, we will test the long-term control provided by oral supplementation of vitamin D versus placebo in a randomized, superiority, double-blind, parallel-group trial. The primary outcomes are (1) repeat measures of the PO-SCORAD severity score over 1 year and (2) cumulate consumption of TAT (number of tubes) during the winter. They will be tested following a hierarchical testing procedure. The secondary outcomes will be measures repeated over 2 years of investigator-based severity scores, patient-reported severity and quality of life scores, serum vitamin D levels, weeks during which the disease is well-controlled, inter-visit cumulate consumption of TAT, and synthetic patient-reported satisfaction at the end of each winter.

DISCUSSION:

This study includes two separate 2-year pragmatic trials designed to evaluate the efficacy of vitamin D supplementation and pro-active phototherapy for primary care atopic dermatitis patients receiving TAT on long-term control of disease activity. The experimental design enables the study of both interventions and exploration of the interaction between vitamin D and phototherapy. A pragmatic trial is particularly suited to the assessment of long-term control. This study explores the possibility of new and safe therapeutic strategies for the control of long-term atopic dermatitis, and is an example of efficacy research that is unlikely to be sponsored by industrialists. A potentially effective low-cost therapeutic strategy for long-term control is essential for patients and public health. TRIAL REGISTRATION ClinicalTrials.gov Identifier NCT02537509 , first received 1 September 2015.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Estaciones del Año / Terapia Ultravioleta / Colecalciferol / Suplementos Dietéticos / Dermatitis Atópica / Antiinflamatorios Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Estaciones del Año / Terapia Ultravioleta / Colecalciferol / Suplementos Dietéticos / Dermatitis Atópica / Antiinflamatorios Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline / Prognostic_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Trials Asunto de la revista: MEDICINA / TERAPEUTICA Año: 2019 Tipo del documento: Article País de afiliación: Francia